bluebird bio Stock News

The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.

Bluebird bio said on Monday it has agreed to sell its priority review voucher for $103 million, if it gets the U.S. Food and Drug Administration's approval for its gene therapy for sickle cell disease

Are you looking for the best penny stocks to buy now? Today might be your day

Bluebird Bio should make progress with its two approved therapies in the next year. It could also launch another one, which is under review for approval, by early 2024.

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD

CRISPR Therapeutics and Bluebird Bio each have potential growth catalysts coming in the next 12 months. CRISPR Therapeutics has a powerful ally and plenty of cash.

The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebird bio stock imply a gain of 99% over the next 12 m

Bluebird Bio is strapped for cash, and a lot of must-do spending is coming up. It will likely need to scale up its clinic footprint while also launching a new medicine.

Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative afte

Bluebird Bio has two approved gene-editing treatments, but they aren't generating much sales yet. The small-cap biotech company could earn another approval by the end of the year.

The Nasdaq has taken a rather large hit in recent weeks, sinking about 7.5% between July 18 and Aug 17. Two of the main reasons for the decline are worries about U.S. inflation and the Chinese econom

bluebird (BLUE) announces that its gene therapy, lovotibeglogene autotemcel, developed for sickle cell disease, will not be scheduled for advisory committee meeting, thereby accelerating the path for

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene au

Bluebird Bio (BLUE) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.29 per share a year ago.

Bluebird's approved gene-editing therapies have a limited combined market opportunity. However, the company could launch another one within a year.